A Study to Determine Enzalutamide Long-term Safety and Efficacy After Anti-androgen Therapy for CRPC

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

160 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-01-26

Study Completion Date

2021-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective observational study to evaluate effectiveness and safety of Enzalutamide for Castration Resistant Prostate Cancer (CRPC) patients who decided to administer Enzalutamide after anti-androgen therapy.

CRPC Patients who are observed PSA or disease progression after anti-androgen therapy and decided to administrate Enzalutamide will dose the Enzalutamide 160 mg orally once daily and observed the practical treatment. Total research term is for 4 years, consists of 2-year case registration terms and 2-year observational terms.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Castration Resistant Prostate Cancer (CRPC)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with histologically or cytologically confirmed prostate cancer.
2. Patients who are receiving or received continuous androgen deprivation therapy using both gonadotropin-releasing hormone (GnRH) agonist and antagonist (medical castration), or both testicles removal by surgery (surgical castration).
3. Castration resistant prostate cancer (CRPC) patients who are observed disease progression after castration treatment and implied the treatment resistant.
4. CRPC patients who conducted anti-androgen alternating therapy as shown below 1) and are observed one or more of disease progression shown as below 2) during or after the therapy and decided to administer enzalutamide.

Note 1) anti-androgen alternating therapy is defined as the therapy of flutamide administration after bicalutamide.

Note 2) Disease progression criteria during or after anti-androgen alternating therapy

① PSA progression during or after anti-androgen alternating therapy: PSA increased more than 25% compare to the lowest test results after initial dose of anti-androgen alternating therapy (flutamide) and the increasing is more than 2ng/ml.

②Confirmed disease progression of soft tissue lesion defined as RECIST v1.1.

③Confirmed disease progression of bone lesion defined as 2 or more of new appearance of bone lesion on bone scintigraphy.
5. Patients with the Eastern Cooperative Oncology Group (ECOG) performance status 0-2
6. Patients who have signed written informed consent to participate in this study

Exclusion Criteria

1. Patients who is administering or have administration history of enzalutamide, abiraterone, docetaxel or cabazitaxel
2. Patients with history of seizure or predisposing disease of seizure
3. Patients with severe liver dysfunction
4. Patients with a previous history of hypersensitivity to any component of drugs which will be administered in this study
5. Patients who considered to be inappropriate for the study participation by the investigator

Minimum Eligible Age

20 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Norio Nonomura, MD, Ph.D.

Role: STUDY_CHAIR

Osaka University Graduate School Of Medicine, Department of Urology

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UMIN000019855

Identifier Type: OTHER

Identifier Source: secondary_id

TRIGU1517

Identifier Type: -

Identifier Source: org_study_id